Who
Brian Adams
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Kymera Therapeutics; Chief Legal Officer, Relay Therapeutics; General Counsel and Secretary, Keryx Biopharmaceuticals.
In numbers
- Trades disclosed
- 105
- Buys
- 1
- Sells
- 67
- Bought
- $200K
- Sold
- $3.8M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 15 Apr 2015
- Last trade
- 4 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Sep 2026filed 4 Sep 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $140K1,209 at $115.55 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $353K3,025 at $116.81 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $251K2,137 at $117.57 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $140K1,209 at $115.55 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $353K3,025 at $116.81 | filing |
| 4 Sep 2026filed 4 Sep 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $251K2,137 at $117.57 | filing |
| 2 Mar 2026filed 4 Mar 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,125 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,250 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,250 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,125 at $0.00 | filing |
| 3 Sep 2025filed 3 Sep 2025 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —105,000 at $0.00 | filing |
| 3 Sep 2025filed 3 Sep 2025 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Code A | —52,500 at $0.00 | filing |
| 29 Jul 2025filed 30 Jul 2025 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $67K18,276 at $3.68 | filing |
| 28 Jul 2025filed 30 Jul 2025 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $6,1221,637 at $3.74 | filing |
| 30 Apr 2025filed 30 Apr 2025 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $39K12,943 at $3.00 | filing |
| 28 Apr 2025filed 30 Apr 2025 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $5,2111,644 at $3.17 | filing |
| 27 Mar 2025filed 31 Mar 2025 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $846298 at $2.84 | filing |
| 30 Jan 2025filed 30 Jan 2025 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $92K20,791 at $4.42 | filing |
| 28 Jan 2025filed 30 Jan 2025 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $156K33,688 at $4.63 | filing |
| 28 Jan 2025filed 30 Jan 2025 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Code A | —139,141 at $0.00 | filing |
News
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)KYMR · prnewswire.com · 12 Oct 2026
0 headlines in the last 90 days name Brian Adams; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.